ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: We focused on dasatinib, which is known to be a Src inhibitor and is used for targeting BCL-ABL fusion protein in chronic myelocytic leukemia and for targeting Philadelphia chromosome in acute lymphatic leukemia [34].